A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT ID: NCT04685226
Last Updated: 2025-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
310 participants
INTERVENTIONAL
2020-09-27
2028-02-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
NCT05745623
Clinical Study of ICP-192 in Solid Tumors Patients
NCT03758664
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
NCT05372120
Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
NCT07136558
Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors
NCT03472352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ICP-723
ICP-723
ICP-723
ICP-723 is a white, round, uncoated table
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICP-723
ICP-723 is a white, round, uncoated table
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age:
Adult Cohort: Age ≥ 18 years; Adolescent cohort: 12 ≤ years \< 18 years.
3. At least one measurable lesion as per RECIST1.1 criteria, or for primary CNS tumors, at least one measurable lesion as per RANO or INRC criteria.
4. Adult cohort: ECOG PS score of 0-1;
5. Adolescent cohort: Karnofsky (age ≥ 16 years) or Lansky (age \< 16 years) PS score \> 60.
6. Life expectancy \> 3 months.
7. Female patients or male patients of childbearing potential, who agree to use medically acceptable effective methods of birth control throughout the study up to 12 weeks after the last dose of the study treatment.
8. Patients who have signed the Informed Consent Form voluntarily and agree to follow the therapeutic regimen and the visit schedule.
Exclusion Criteria
2. Prior anti-cancer treatment within 28 days prior to the first dose.
3. Major surgical procedures within 4 weeks or minor surgical procedures within 2 weeks prior to the first dose of the study drug.
4. A history of allergic disease, severe drug allergy, known hypersensitivity to any component of the ICP-723 tablet formulation.
5. Other situations that, in the investigator's opinion, would make the subject unsuitable for participation in the study.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing InnoCare Pharma Tech Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
The First Medical Center of the Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Cancer Hospital Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Sun Yat-Sen University Cancer Center
Guangdong, Guangzhou, China
Shijiazhuang People's Hospital
Shijiazhuang, Hebei, China
Cancer Hospital Affiliated to Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Henan Provincial People's Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer hospital
Changsha, Hunan, China
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
The first affiliated hospital Zhejiang university school of medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mingjun Zhang, MD
Role: primary
Jian Fang, MD
Role: primary
Yi Hu, MD
Role: primary
Weidong Li, MD
Role: primary
Herui Yao, MD
Role: primary
Zhong Lin
Role: primary
Xiaofeng Pei
Role: backup
Jingran Wang, MD
Role: primary
Baogang Liu, MD
Role: primary
Shuangshuang Guo
Role: primary
Quming Wang, MD
Role: primary
Shundong Cang, MD
Role: primary
Xingya Li, MD
Role: primary
Xiaorong Dong, MD
Role: primary
Lin Wu, MD
Role: primary
Yongqian Shu, MD
Role: primary
Yong Mao, MD
Role: primary
Junhe Li, MD
Role: primary
Zhehai Wang, MD
Role: primary
Jing Wang, MD
Role: primary
Hongxia Lu, MD
Role: primary
Runxiang Yang, MD
Role: primary
Tao Li, MD
Role: primary
Nong Xu, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ICP-CL-00501
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.